Idarubicin - Pfizer
Alternative Names: DMDR; FCE 22723; Idamycin; Idarubicin hydrochloride; Idarubicinol; IMI 30; NSC 256439; Zavedos; Zavedos OralLatest Information Update: 24 Oct 2021
At a glance
- Originator Pfizer
- Class Antineoplastics; Cytostatic antibiotics; Daunorubicins
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute myeloid leukaemia; Acute nonlymphocytic leukaemia; Breast cancer; Leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
- 07 Sep 2000 Investigation in Chronic myeloid leukaemia (IV)
- 07 Sep 2000 Launched for Acute lymphoblastic leukaemia in Argentina (IV)